Paradigm's Phase 3 global study of repurposed injectable Pentosan Polysulfate Sodium (iPPS) for knee osteoarthritis is approaching a pivotal interim dataset (Day 112), with results expected in August. At 18c, the stock is trading below the 19c raise recently conducted to fund the company through that milestone. Strong interim results could trigger a material re-rating and/or catalyse a partnership to progress the NDA and commercialisation.

I have taken a small initial position with the intention of adding at attractive prices following the interim data release if the opportunity arises. The current sizing also reflects the possibility that an entry point does not materialise post-release, in which case I retain some exposure to any upside.

The modest initial weighting reflects the binary nature of this investment. While there are several adjacent indications available should the knee OA program fall short, pursuing them would require substantial additional capital, likely raised at materially lower prices, which would catastrophically dilute existing shareholders.

My read of the efficacy data to date is cautiously positive, though I acknowledge the results are difficult to interpret without specialist expertise. The outcome is not uniform across patients, and the Phase 3 study will be the true test of statistical significance. The use of a subjective scale assessment is entirely appropriate for this indication, but does introduce an element of ambiguity in evaluating the results.

The repurposed nature of the drug is a meaningful positive from a safety standpoint, even given the change in administration route (subcutaneous injection). However, it introduces commercial risk around the durability of patent protection and the timeline before generic competition emerges. In theory, "Method of Use" patent protection extends to 2040 for the treatment of OA with bone marrow edema, but the underlying molecule PPS is off-patent. The company also holds a 25-year exclusive supply agreement with bene pharmaChem (the only FDA-approved PPS manufacturer), though the enforceability of this arrangement and the feasibility of a competitor obtaining FDA manufacturing approval remain open questions.

If approved and successfully commercialised, this treatment has genuine blockbuster potential. It is well-positioned as a non-steroidal, non-opioid, non-addictive therapy for chronic pain in a large and underserved market of approximately 30 million patients in the US alone, with an annual revenue opportunity in excess of US$2,000 per patient. The company is also actively broadening its PPS pipeline, including the 2025 acquisition of Proteobioactives and its oral PPS and COX-2 inhibitor combination therapy, which provides longer-term optionality.

Despite being a mid-Phase 3 asset with substantial commercial potential, a sub-A$100m valuation is not surprising given the risk factors outlined above. Were this company listed in the US with stronger patent protection, it would likely command 5–10x the current valuation at this stage and potentially another order of magnitude beyond that if it successfully navigates the NDA process.

Thank you to the many in the SM community over a long period who have followed and written on PAR to bring it to my attention and provide great insights.  Credit to @GazD 's endurance on this one and thanks to @mikebrisy for a clear perspective on possible value.

High risk, high reward. Small position sizing warranted.

Disc: I own RL